Rocket Pharmaceuticals(RCKTW)

NEW YORK, NYPharmaceutical1 H-1B visas (FY2023)

Focus: Rocket Pharmaceuticals is a public-stage gene therapy company focused on neurological and rare genetic disorders, headquartered in New York with a lean operational footprint.

Neurology

Profile data last refreshed 4h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

11+2 this month

Stable — net +2 jobs in 30d

6 added, 4 removed. Backfill posture.

2 recent layoff filings (12 mo) — 160 affected

7/1/2025 — Cranbury, NJ · 80 affected · Layoff
7/1/2025 — Cranbury, NJ · 80 affected · Layoff

Source: state DOL filings via Big Local News

Should You Work at Rocket Pharmaceuticals?

AI assessment

Rocket is a bet-the-company gene therapy play with clinical diversity but pre-revenue cash burn trajectory; best for scientists seeking frontier research exposure willing to accept equity volatility and uncertain timelines.

Why Work Here

Deep gene therapy expertise with 36 active clinical trials across rare diseases and high unmet need indications like Fanconi Anemia and Danon Disease

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Early-stage

36 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$0K

Pipeline & Clinical Trials

Transarterial infusion chemotherapy

Unresectable Colorectal Cancer

N/A

Clinical Trials (1)

NCT07333053Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer

N/A

Help build intelligence for Rocket Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides stability and equity upside potential versus pre-revenue biotech

Diversified pipeline spanning Phase 1-4 with multiple shots on goal across neurology, hematology, and cardiac indications

Watch Out For

Pre-revenue biotech model with $171M R&D spend against negative $258.7M net income in FY2025, signaling years to profitability
Only 9 active job openings and minimal headcount visibility suggest limited growth runway or potential near-term hiring freeze
Noisy pipeline data (36 programs include observational studies, devices, and standard-of-care comparators rather than pure Rocket-owned assets) raises execution clarity questions

Generated by Claude from Rocket Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Novel Pleural Fluid, Biopsy and Serum Biomarkers for the Investigation of Pleural Effusions

Respiratory Disease

N/A

Clinical Trials (1)

NCT03661801Novel Pleural Fluid, Biopsy and Serum Biomarkers for the Investigation of Pleural Effusions

N/A

Heart Transplant

Danon Disease

N/A

Clinical Trials (1)

NCT05548855Natural History of Danon Disease

N/A

Vacuum-Based IPC

Pleural Effusion

N/A

Clinical Trials (1)

NCT03831386Gravity Versus Vacuum Based Indwelling Tunneled Pleural Drainage System

N/A

The Natural History of Danon Disease

Danon Disease

N/A

Clinical Trials (1)

NCT03766386The Natural History of Danon Disease

N/A

no interventions

Bronchopulmonary Dysplasia

N/A

Clinical Trials (1)

NCT06082414Systemic Management in Extremely Preterm and Extremely Low Birth Weight Infants

N/A

Digital Pleural Manometry

Pleural Effusion, Malignant

N/A

Clinical Trials (1)

NCT02805062Manometry vs Clinical Assessment in the Detection of Trapped Lung in Patients With Suspected Pleural Malignancy

N/A

Pleural procedures

Malignant Pleural Effusion

N/A

Clinical Trials (1)

NCT04793607Interventions for Malignant Pleural Effusions Impact on Fatigue

N/A

No intervention

Danon Disease

N/A

Clinical Trials (1)

NCT06214507Danon Disease Natural History Study

N/A

PKP2-ACM Natural History Study

Cardiomyopathies

N/A

Clinical Trials (1)

NCT06644742PKP2-ACM Natural History Study

N/A

EDIT Management

Pleural Effusion, Malignant

N/A

Clinical Trials (1)

NCT03319186EDIT Management Feasibility Trial

N/A

BAG3-DCM Natural History Study

Dilated Cardiomyopathy (DCM)

N/A

Clinical Trials (1)

NCT07486752BAG3-DCM Natural History Study

N/A

Device: Butterfly iQ

Covid19

N/A

Clinical Trials (1)

NCT04967729COVID-19 and Lung Ultrasound Utility

N/A

no intervention

Neonatal Acute Respiratory Distress Syndrome(ARDS)

N/A

Clinical Trials (1)

NCT03311165Epidemiological Study of Neonatal Acute Respiratory Distress Syndrome (ARDS)

N/A

Group-based Acceptance and Commitment Therapy

Acute Stroke Patients With Depression

N/A

Clinical Trials (1)

NCT05727358Effectiveness of Group Acceptance and Commitment Therapy in Treating Acute Stroke Patients With Depression

N/A

Delayed transanal pull-through anastomosis

Rectal Cancer

N/A

Clinical Trials (1)

NCT06662643A Clinical Trial Comparing Staged Turnbull-Cutait Pull-through Anastomosis With Direct Anastomosis Plus Prophylactic Ileostomy in the Treatment of Low Rectal Cancer After Internal Sphincter Resection

N/A

Safety and efficacy assessments

Fanconi Anemia Complementation Group A

N/A

Clinical Trials (1)

NCT04437771Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy

N/A

Clostridium butyricum

Rectal Cancer

N/A

Clinical Trials (1)

NCT07369830The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function

N/A

Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)

Leukocyte Adhesion Deficiency

N/A

Clinical Trials (1)

NCT06282432Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)

N/A

RP-A601

PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)

PHASE_1

Clinical Trials (1)

NCT05885412A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Phase 1

RP-L102

Fanconi Anemia Complementation Group A

PHASE_1

Clinical Trials (1)

NCT03814408A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A

Phase 1

Bone Marrow Aspiration

Fanconi Anemia

PHASE_1

Clinical Trials (1)

NCT01331018Gene Therapy for Fanconi Anemia

Phase 1

RP-L201

Leukocyte Adhesion Defect - Type I

PHASE_1

Clinical Trials (1)

NCT03825783A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

Phase 1

RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74

Dilated Cardiomyopathy (DCM)

PHASE_1

Clinical Trials (1)

NCT07137338A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

Phase 1

RP-A501

Danon Disease

PHASE_1

Clinical Trials (1)

NCT03882437Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B

Phase 1

RP-L301

Pyruvate Kinase Deficiency

PHASE_1

Clinical Trials (1)

NCT04105166Gene Therapy for Pyruvate Kinase Deficiency (PKD)

Phase 1

RP-L401

Infantile Malignant Osteopetrosis

PHASE_1

Clinical Trials (1)

NCT04525352A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis

Phase 1

RP-L201

Leukocyte Adhesion Defect - Type I

PHASE_1_2

Clinical Trials (1)

NCT03812263A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

Phase 1/2

RP-L102

Fanconi Anemia Complementation Group A

PHASE_2

Clinical Trials (1)

NCT04248439Gene Therapy for Fanconi Anemia, Complementation Group A

Phase 2

RP-L301

Pyruvate Kinase Deficiency

PHASE_2

Clinical Trials (1)

NCT06422351Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency

Phase 2

RP-A501

Danon Disease

PHASE_2

Clinical Trials (1)

NCT06092034A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Phase 2

RP-L102

Fanconi Anemia Complementation Group A

PHASE_2

Clinical Trials (2)

NCT04069533Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A

Phase 2

NCT07527975Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102

N/A

Tislelizumab

Locally Advanced Rectal Carcinoma

PHASE_2_3

Clinical Trials (1)

NCT06312982A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer

Phase 2/3

SIS-reinforced anastomosis

Rectal Cancer

PHASE_4

Clinical Trials (1)

NCT07209787SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak

Phase 4

Xuebijing

Pulmonary Disease, Chronic Obstructive

PHASE_4

Clinical Trials (1)

NCT02937974Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD

Phase 4

Standard First-Line Therapy

Unresectable Colorectal Cancer

Phase 2/3

Clinical Trials (1)

NCT07509398FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer

Phase 2/3

Interview Prep Quick Facts

Portfolio: 37 clinical trials

Top TAs: Oncology, Hematology, Respiratory

H-1B (2023): 1 approval

SEC Filings: 2 available

Open Roles: 11 active jobs

Therapeutic Area Focus

7 pipeline

6 pipeline

4 pipeline

3 pipeline

1 pipeline

Financials (FY2025)

Revenue

R&D Spend

$171M3%

Net Income

-$259M

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (2)

2025-07-01

80 employees affected— Cranbury, NJ

source

2025-07-01

80 employees affected— Cranbury, NJ

source

Source: state DOL filings, aggregated via Big Local News

No public FDA or regulatory red flags, but pre-revenue cash burn and declining cash reserves present material solvency risk within 18-24 months without licensing deal or capital raise.

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Rocket Pharmaceuticals(RCKTW)

Should You Work at Rocket Pharmaceuticals?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (11)

Associate Director, Quality Control - Stability and Raw Materials

Training Manager

Director, Gene Therapy Clinical Science

Specialist, Quality Document Control

Director, Regulatory Affairs – CMC

Senior Director, Quality Assurance - Commercial & Compliance

Vice President, Head of Cardiovascular Medicine

Senior Vice President, Regulatory Affairs

Senior Director, Quality Control

Associate Medical Director, Gene Therapy Clinical Development - Cardiology

Senior Director, Marketing & Commercial Development

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (2)